142 related articles for article (PubMed ID: 37484140)
1. Auxiliary Diagnosis and Prognostic Value of Dehydrogenase/Reductase 2 (DHRS2) in Various Tumors.
An Z; Bo W; Qin J; Jiang L; Jiang J
Iran J Public Health; 2023 Jun; 52(6):1150-1160. PubMed ID: 37484140
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
Exp Cell Res; 2024 Jun; 439(1):114055. PubMed ID: 38704080
[TBL] [Abstract][Full Text] [Related]
3. STAMBPL1 promotes the progression of lung adenocarcinoma by inhibiting DHRS2 expression.
Yang X; Ling L; Li C; Hu T; Zhou C; Chen J; Wang Y; Hu L
Transl Oncol; 2023 Sep; 35():101728. PubMed ID: 37393834
[TBL] [Abstract][Full Text] [Related]
4. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma.
Zhou Y; Wang L; Ban X; Zeng T; Zhu Y; Li M; Guan XY; Li Y
Oncogene; 2018 Feb; 37(8):1086-1094. PubMed ID: 29106393
[TBL] [Abstract][Full Text] [Related]
5. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease.
Li Z; Liu H; Bode A; Luo X
Eur J Pharmacol; 2021 May; 898():173972. PubMed ID: 33652058
[TBL] [Abstract][Full Text] [Related]
7. DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma.
Luo X; Li N; Zhao X; Liao C; Ye R; Cheng C; Xu Z; Quan J; Liu J; Cao Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):300. PubMed ID: 31291971
[TBL] [Abstract][Full Text] [Related]
8. A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.
Wu X; Chen H; You C; Peng Z
Hereditas; 2023 May; 160(1):21. PubMed ID: 37170390
[TBL] [Abstract][Full Text] [Related]
9. Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer.
Lv Z; Qi L; Hu X; Mo M; Jiang H; Fan B; Li Y
Front Mol Biosci; 2021; 8():631067. PubMed ID: 33665207
[No Abstract] [Full Text] [Related]
10. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
12. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Li Z; Tan Y; Li X; Quan J; Bode AM; Cao Y; Luo X
Cell Death Dis; 2022 Oct; 13(10):845. PubMed ID: 36192391
[TBL] [Abstract][Full Text] [Related]
13. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
Ning Y; Li Y; Wang H
Front Genet; 2023; 14():1108167. PubMed ID: 36713082
[No Abstract] [Full Text] [Related]
14. PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer.
Chen C; Shang A; Gao Y; Huang J; Liu G; Cho WC; Li D
Front Mol Biosci; 2022; 9():968458. PubMed ID: 36203873
[No Abstract] [Full Text] [Related]
15. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma.
Huang X; Tan J; Chen M; Zheng W; Zou S; Ye X; Li Y; Wu M
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371463
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker.
Zhou B; Gao S
Front Mol Biosci; 2021; 8():648402. PubMed ID: 33968987
[TBL] [Abstract][Full Text] [Related]
18. [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].
Wang H; Li W; Zhang D
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Apr; 42(4):473-485. PubMed ID: 35527483
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
20. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
Front Immunol; 2022; 13():857308. PubMed ID: 35345673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]